For pharma market access and commercial teams, the UK access pathway can look deceptively straightforward: secure MHRA approval, achieve a positive NICE recommendation, and then expect local systems to make the medicine available within the required timeframe.

In reality, uptake is rarely that linear.

A positive NICE HTA recommendation matters. In most cases, it is worth pursuing because it provides national endorsement, supports the cost-effectiveness case, and gives payers a clear reason to act. But it is not the only factor shaping uptake, and the scale of its impact depends heavily on what else is happening in the local system.

This is becoming an increasingly important strategic question for companies. NICE HTA requires significant investment, often costing hundreds of thousands of pounds once evidence generation, submission development and internal resource are considered. Unsurprisingly, more companies are asking whether that investment is still worth it.

Our view, based on work with payers and conversations across the access landscape, is that NICE HTA is usually worth it. But its value is greatest when it helps a product rise above competing local priorities.

Payers are under pressure from every direction. Structural change across the NHS, uncertainty around future responsibilities, reduced workforce capacity and tight budgets all affect how quickly local systems can respond to new medicines. Even where a product has national approval, payers still have to decide what gets attention first.

That means NICE approval can act as a catalyst, but it lands in a crowded environment.

Where a product addresses an area of high unmet need, has strong clinician support, attracts visible patient or charity advocacy, or offers a clear opportunity to reduce service pressure, it may already be moving up the payer priority list. In those cases, NICE strengthens and legitimises the case for action.

By contrast, where the current standard of care is viewed as acceptable, the pathway is not under scrutiny, and there is limited pressure from clinicians or patients to change, NICE HTA can be especially valuable. It provides an external, objective reason to revisit the status quo. It can turn a medicine from “interesting but not urgent” into something local systems need to actively consider.

This is where understanding payer priorities becomes critical.

Payers are not simply asking whether a medicine has a positive NICE recommendation. They are asking whether it is urgent, affordable, implementable and valuable in the context of their local challenges.

In practice, payer prioritisation is often shaped by:

• Medical need and whether the current pathway is clearly failing patients
• Budget impact, including both additional cost and potential savings
• Strength of advocacy from clinicians, patients, PAGs and charities
• Value to the wider NHS, such as pathway efficiency, capacity release or reduced downstream burden
• Ease of implementation, including workforce, diagnostics, pharmacy and pathway ownership
• Scale of local financial pressure, particularly in high-cost areas for ICSs

These priorities can amplify the impact of NICE HTA or limit its incremental effect.

A positive NICE recommendation for a highly scrutinised therapy area with strong clinical pull may accelerate a decision that local payers were already moving towards. A positive recommendation in a lower-priority area may still be important, but adoption may be slower if implementation is complex or the perceived need to change is weak.

This is why formulary status and real-world uptake can still lag behind national guidance. At a recent BHBIA conference, analysis suggested that fewer than 30% of products were included on local formularies within 90 days of NICE TA publication. This reflects what many in the industry recognise: national recommendation does not always translate quickly into local availability or usage.

The proposed single national formulary may eventually reduce duplication and variation, and it is increasingly mentioned by payers as something on the horizon. But there is still no definitive implementation model, and local readiness will continue to matter. Even with greater national consistency, systems will still need to operationalise guidance, update pathways, engage clinicians and manage budgets.

For pharma, the implication is clear. NICE HTA should not be viewed in isolation. It should be considered alongside the wider payer environment, the strength of the clinical and patient case, the budget story, and the practical burden of implementation.

The better question is not simply: “Is NICE HTA worth it?”

It is: “How much will NICE HTA change payer behaviour for this product, in this therapy area, at this moment?”

Impact Health works closely in this space, helping companies understand how sub-national high-cost drug payers think, what messages resonate, and which channels influence engagement. Our payer tracking study monitors trends, challenges and communication preferences among these payer audiences, providing practical insight into how priorities are shifting.

In a pressured NHS, payers cannot prioritise everything. NICE HTA remains a powerful catalyst, but its real value depends on how it interacts with the other factors driving local decision-making.

For companies preparing for launch or questioning the value of HTA investment, payer insight is essential. It helps clarify where NICE will make the biggest difference, where other catalysts may already be in play, and what is needed to turn national recommendation into meaningful uptake.

To learn more about Impact Health’s payer tracker, please get in touch.

jamie.margerison@impacthealthmr.com